Sowmya Viswanathan has a regulatory consulting company, which does not conflict in anyway with any work done for this paper. The other authors have no conflicts of interest.
Introduction
Osteoarthritis (OA) is a common joint disease affecting 1 in 10 Canadians and is expected to increase to 1 in 4 by 2040. It is a lasting condition in which cartilage breaks down, causing bones to rub against each other, resulting in stiffness, pain and loss of joint movement. Currently, there are few effective treatments available for patients suffering from osteoarthritis. Mesenchymal Stromal Cells (MSCs) are cells that can be obtained from bone marrow and other tissues. Early clinical data shows improvements in cartilage volume and quality [1] [2] [3] [4] [5] [6] and secretion of immunomodulatory factors. Our pioneering Canadian trial (NCT02351011, clinicaltrials.gov) using autologous bone-marrow-derived MSCs showed significant improvement in symptoms and quality of life relative to baseline in osteoarthritic patients; for the first time, we showed clinically that MSCs reduced synovial joint levels of pro-inflammatory macrophages, a potent inflammatory mediator, suggestive of a possible mechanism of action [7] . Macrophages are the most prevalent immune cell in OA joints [8] , are elevated in OA compared to healthy joints [9] , and contribute to synovial inflammation and fibrosis, characteristic of OA.
Understanding the immediate post-transplant joint environment by visualizing and monitoring localization and persistence of MSCs in a direct, non-invasive, longitudinal manner will address a major barrier in evaluating the success of MSC therapies in OA.
Although early clinical trial results with MSCs are promising, unanswered questions regarding dosing, timing, frequency, interaction with macrophages, and mechanism of action of MSC persist.
Previously MSCs have been imaged in animal models using superparamagnetic iron oxide nanoparticles (SPIO) such as such as ferumoxides and ferucarbotran (i.e. Feridex™, Endorem® and Resovist™) because of their ease of use in stem cells, greater sensitivity for MR imaging compared to other contrast agents including gadolinium and CellSense, and lack of requirement for specialized multinuclear MRI systems for visualization.
Ultrasmall SPIOs (i.e. ferumoxytol or Feraheme™) are introduced into cells by endocytosis and require transfection protocols using protamine sulfate and heparin [10] .
Ferumoxytol has been clinically-approved by Health Canada and the Food and Drug Administration (FDA) for treatment of anemia in chronic-kidney disease patients, making it an attractive cell tracking agent.
Adipose-tissue MSCs have previously been labeled with ferumoxytol and feasibility of imaging in vitro and in vivo in rats models of osteochondral defects has been shown [11] .
Other studies have also imaged MSCs labeled with other iron-nanoparticles and demonstrated persistence out to 5 weeks [12] in Hartley strain guinea pigs, and persistence out to 6 months in immunosuppressed NOD-SCID mice [13] .
In this study, we attempted to demonstrate feasibility of labeling and MRI tracking of murine MSCs in a murine joint model of mildly inflammatory osteoarthritis that is clinically translatable and relevant. This study serves as a pre-requisite for subsequent clinical translation involving ferumoxytol-labeling of human MSCs intra-articularly injected into knee OA patients. Importantly, we wanted to identify a putative antiinflammatory mechanism of action of MSCs through polarization of monocytes/macrophages in the arthritic joint. Monocytes/macrophages are the most prominent immune effects in OA and their levels correlate with OA severity, which we have recently also correlated with patient-reported pain and symptoms [14] .
Materials & Methods
Cell isolation: Mouse bone marrow stromal mesenchymal cells were isolated from mouse long bones. Briefly, bone marrow was flushed out of mouse long bones (mouse tibiae, femurs), and were cultured in low glucose DMEM, supplemented with 10% FBS and Glutamine for less than 14 days.
Animals: 10 week-old C57BL/6 male mice (n=5/group, Jackson Laboratories) were used for our studies. Mice underwent surgery (destabilization of medial meniscus (DMM) or sham surgery) and injected with either fluorescent dye-(DiR) labeled or DiR+ferumoxytollabeled (DiR+Fe) mesenchymal stem cells (MSC, 50x10 3 MSCs/mouse) or saline (control), and were thus separated into 4 treatment groups: i) DMM+Saline; ii) DMM+DiR+Fe-MSC; iii) DMM+DiR MSC; iv) SHAM+DiR+Fe-MSC and saline in contralateral knee ( Fig 1) . All mice were fed ad libitum and were allowed to roam freely in cages throughout the study. (n=4 for 1 week, n=5 for 2 and 4 week timepoints). DiR: 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindotricarbocyanine Iodide. B. Timeline: Mice were assessed for total blood count, blood biochemistry, histopathology and MSC persistence in knee joints via MRI (On day 0 and day 3, and 1, 2 or 4 weeks post-injection). Dotted lines indicate that only one of the timepoints were selected for MRI.
Surgical induction of instability: DMM -DMM surgery was performed as described by
Glasson et al. [15] . Briefly, mice were induced with 2% isoflurane, and their right knees were shaved and prepped with iodine. At 90 degrees of flexion, the joint line was identified using a straight sharp tip micro probe (0.025 mm) facilitating the establishment of a medial para-patellar intra-articular port. A 3 mm skin incision was made over the medial portal using a knife with a number 10 blade. Following this, the capsule was incised in line with the skin incision medial to the patellar ligament. With the help of a microcurette (0.5 mm), the fat pad was dissected and the medial meniscotibial ligament (MMTL) was exposed.
The MMTL is a translucent transverse band that connects the medial meniscus (MM) to the tibial plateau. Under direct vision, the MMTL was incised using a straight tip vannas spring scissors (0.075 mm). Care was taken not to damage the cartilage or other soft tissue structures. During the destabilization, bleeding encountered was controlled with direct pressure using absorption spears. The destabilization was confirmed using a probe against the freely mobile medial meniscus. The capsule and skin were then sutured (8-0). Buprenorphine (0.2 mg/mL, Indivior) was injected subcutaneously at the time of surgery and 24 hours post-surgery for pain maintenance. Mice were allowed to roam freely in their cages after surgery, and monitored closely for post-surgical complications.
Cell labeling and injection:
A subset of research animals (DMM and sham) received ferumoxytol-labeled MSC. Prior to intra-articular injection, MSCs were incubated for 2h with 50 µg Fe/mL ferumoxytol (Feraheme™; AMAG Pharmaceuticals Inc., Waltham, MA, USA) as per Thu et al in serum-free DMEM containing 3 U/mL heparin and 60 mg/mL protamine sulfate at 37 o C, 5% CO 2 [10] . After this initial incubation, cells were supplemented with complete low glucose DMEM (containing 10% FBS) and further incubated at 37 o C, 5% CO 2 overnight. After labeling, cells underwent sequential PBS washing before and after dissociation. All cells (Fe-MSCs and unlabeled MSCs) were stained with the lipophilic fluorescent dye DiR (also called DiIC18 (7) , full chemical name:
1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindotricarbocyanine Iodide) for 30 minutes and then washed three times with PBS before quantification. DiR is a lipophilic, near-infrared fluorescent cyanine dye. Cell viability was assessed by trypan blue exclusion assay, and cells were subsequently intra-articularly injected into mice in accordance to their respective groups (Fig 1) .
Intra-articular knee injections:
Mice were induced with 2% isoflurane, and their knees were depilated, prepped and positioned as in the DMM surgery. The patellar ligament was identified as a pearl-white vertical band. Using a 10 µL Hamilton Syringe with custom 30G needle, the joint line was identified, and the needle was inserted along the medial border of the patellar ligament, keeping it in line with the joint line, slowly advancing it till loss of resistance was appreciated. Following this, the plunger was slowly pushed to deliver 4 µL of DiR+Fe-MSCs or DiR MSCs (5x10 4 cells) into the joint space. Once the MSCs were delivered, the needle was removed, and the knee joint was flexed and extended slowly.
Saline was used as a vehicle control treatment.
Magnetic resonance imaging and analysis: All MRI examinations were performed using a 3 Tesla (T) GE Discovery MR750 whole-body clinical MR scanner with a custom-build high-performance gradient insert coil (maximum gradient strength = 500 mT/m and peak slew rate = 3000 T/m/s) and a custom solenoid radiofrequency mouse body coil (4 cm long, 3 cm diameter). Mice were anaesthetized with 2% isoflurane. Whole-body mouse images were acquired with the following three dimensional balance steady state free precession Samples were analyzed in triplicate for β2-Microglobulin (B2M), inducible NO synthase (iNOS), Interleukin 10 (IL10), Transforming growth factor beta (TGFβ1), Interleukin 6 (IL6), Hepatocyte growth factor (HGF), Programmed death-ligand 1 (PDL-1 or CD74) and Cyclooxygenase 2 (COX2 or Prostaglandin endoperoxide synthase 2, PTGS2) (see Table   S1 for detailed primer sequences). Thermal cycling was performed with QuantStudio5 (ThermoFisher): 95°C, 2 min followed by 40 cycles of 95°C, 15s and 60°C, 20s. Relative fold change in expression levels were calculated using the 2^-ΔΔCt method, with β2-Microglobulin (B2M) as housekeeping gene [16] . Comparison was determined using paired Student's t-test. Labs PK-6100) for 30 minutes and DAB-horseradish peroxidase substrate detection system. Cells were counterstained with hematoxylin (Vector Labs, H3404) to detect total cells. Sections were subsequently dehydrated and mounted with Permount (ThermoFisher Scientific, SP15-500). Images were taken at 40x and analyzed with Fiji ImageJ software.
Immunohistological Image analysis: Percentage of positively stained CD206 (homeostatic, "M2-like" cells) or F480 (total macrophages) with respect to total cells (stained with Hematoxylin) was quantified to assess synovial inflammation within the DMM or SHAMoperated knee joints. Briefly, 6-8 images were taken of medial knee joint sections at 40x to encompass the synovial tissue adjacent to the medial meniscus. Synovial Inflammation scoring: Synovial inflammation was determined according to OARSI histopathology methods [18] . Briefly, synovial inflammation is graded from 0-4, where 0 denotes no changes to synovial tissue, and 1-4 denotes the spectrum of synovial inflammation that includes: increased proliferation of subsynovial tissue, increased number of lining cell layers, and an increase in infiltration of inflammatory cells.
Results

Viability and phenotypic assessment of ferumoxytol-labeled MSC
There were no differences tri-lineage potential of MSCs labeled with or without ferumoxytol ( Fig S1) . Trypan blue exclusion assay results demonstrated no difference in the viability of unlabeled and ferumoxytol-labeled murine MSCs, at 98.5±1.9% and 94.3±5.9%, respectively ( Fig S2) . The fold change in gene expression normalized using β2-Microglobulin (B2M) on a panel of 7 genes (iNOS, IL10, TGFβ1, IL6, HGF, PDL-1, COX2) showed no significant difference between the unlabeled MSC and Fe-MSCs (n=3 per group) as determined by paired Student's t-test except HGF (*p=0.0341) ( Fig S3) . 
Magnetic Resonance Imaging
Three dimensional whole body anatomical images were acquired that allowed well-defined delineation of experimental mouse knees over time. Representative images of control, sham and DMM surgical knees can be seen in figure 2A . In control mouse knees a hyperintense region corresponding to the fatpad of the tibio-femoral joint was clearly evident (Fig 2A, red arrows) . Both sham and DMM surgeries required the dissection of this fatpad to enable access to the joint and the absence of the fatpad was evident in all imaged sham and DMM surgical knees. Mice were imaged on the same day as, at three days post and either 1, 2 or 4 weeks post intra-articular saline or cell delivery. For sham and DMM surgery mice that received Fe-MSC, MR images confirmed the intra-articular localization of the cells by the presence of distinct signal voids in the joint space (Fig 2A, red arrows). These signal voids were analyzed for void volume and fractional signal loss over time ( Fig 2B&C) . On the day of cell injection, the average volume of the region of signal loss within the surgical knee did not differ significantly between mice with different surgical preparations with a volume of 0.51±0.38 mm 3 in DMM mice and 0.39±0.25 mm 3 in sham mice (Fig 2A) . In all DiR+Fe-MSC injected knees the void volume decreased overtime, however, a region of signal loss persisted in all of these knees at the transplant site until end point. A significantly greater percentage of the initial void volume persisted at 3 days and 1-week post DiR+Fe-MSC cell injection in DMM knees compared to sham knees ( Fig   2B) . By the 4-week end point both surgical groups showed a significant (p<0.0001) reduction in void volume, but DMM surgery mice still retained a void volume of 0.17±0.04 mm 3 which was significantly greater (p=0.001) volume than the 0.06±0.03 mm 3 void volume seen in sham surgery mice (Fig 2A) .
On the day of cell transplantation, the fractional signal loss (FSL) in DiR+Fe-MSC injected surgical knees did not differ significantly with FSL values of 77.0±6.9 and 75.7±6.3 for DMM and sham knees, respectively ( Fig 2C) . DMM surgery mice receiving DiR+Fe-MSC did not show a significant reduction in FSL over the time course of the experiment (Fig 2C) . Conversely, sham surgery mice showed a significant (p=0.0021) 18% reduction is FSL as early as 3 days post injection. The FSL observed in DMM versus sham surgery mice was significantly different (p≤0.05) at all assessed time points after the day of injection ( Fig 2C) . 
Retention of iron signal in MSCs
Histological sections were stained against Prussian Blue to detect presence of ferumoxytol in injected MSCs [19] . Prussian Blue staining was found to localize within the synovial joint, indicating that ferumoxytol-labeled MSCs persisted in the joint space up to 4 weeks after intra-articular injection ( Fig 4A) . Notably, positively stained Prussian-blue labeled MSCs (blue) were detected within macrophages (stained with F480, purple) as early as 1
week after intra-articular injection, suggesting that macrophages engulfed apoptotic MSC bodies during the early inflammatory phase of osteoarthritis ( Fig 4B) . 
Histopathology of Synovial Joints
Cartilage degeneration of mouse joints was graded using the OARSI scoring system. No significant changes were found in cartilage degradation between MSC-treated and salinetreated OA-mice. (Fig 3B) .
Using the OARSI scoring system for synovial inflammation [18] , average synovial inflammation scores (0-4) were determined in DMM-operated mice treated with saline or DiR+Fe-MSCs. Differences in synovial inflammation were detected during the early phase of synovial inflammation (i.e. 3 days) and late inflammation (i.e. 4 weeks) after MSC treatment (p<0.05 respectively).
The substantial decrease in synovial inflammation at 4 weeks after MSC injection corresponded with the prolonged persistence of DiR+Fe-MSCs within the synovial joint, and an increase of homeostatic macrophages at 4 weeks after injection, suggesting that the MSC treatment may be contributing significantly to the infiltration and polarization of macrophages into a more homeostatic phenotype to resolve synovial inflammation within the joint.
Immunohistochemistry
Medial knee sections were stained against CD206 and F480 to determine the amount of homeostatic macrophage and total macrophage infiltration after MSC injection in OAinduced mice (Fig 5A) . We observed that MSC-treatment in DMM mice induced an increasing trend in total macrophage infiltration (p<0.08) compared to saline-treated DMM mice and sham operated mice treated with either MSCs or saline. More notably, there was a significant increase in CD206+ cells in the synovium after MSC treatment in DMMoperated mice, suggesting that MSC treatment led to an increase in macrophage infiltration and polarization towards a homeostatic phenotype (p<0.05, Fig 5B) . Safety of ferumoxytol-labeled MSCs vs. unlabeled MSCs -Safety of ferumoxytol-labeled MSC over a 4-week period was also verified in 35 mice with histology on target organs, and CBC and blood biochemistry (Table S2 and S3 ). Our data shows no difference in readouts between ferumoxytol-labeled and unlabeled MSCs, saline controls or sham animals. 
Discussion
Using a non-invasive clinically-approved tracking method, we have for the first time imaged ferumoxytol-labeled MSC persistence in an immunocompetent clinically translatable mouse model of surgically-induced osteoarthritis (OA). We showed persistence of MSCs out to four weeks after injection, and importantly illustrated a mechanism of actions involving MSCs polarization of joint-specific macrophages to more homeostatic lineages.
Previously, serial scans of xenotransplanted human MSCs (hMSCs) in an osteochondral rat defect model showed that the iron signal of apoptotic, nanoparticle-labeled hMSCs engulfed by macrophages disappeared faster compared to viable hMSCs in T2-weighted MRI images [20] . This corresponded to poor cartilage repair outcomes in rats receiving apoptotic hMSCs.
Delling et al. similarly used a non-vital ovine MSC group in 12 sheep that had OA-induced by bilateral menisectomy and reported significant differences in hypointensity signaling up to 12 weeks between the vital and non-vital MSC groups [21] . Importantly, they observed reduced Prussian Blue staining in sheep receiving the non-vital MSCs by immunohistology compared to vital MSC groups. They did report increased chondrogenic differentiation surrounding regions of iron nanoparticle detection.
We report for the first time, that Prussian Blue staining by immunohistochemistry is largely visible in cells that co-stain for Sca-1, a marker of bone marrow-derived mesenchymal stromal cells [22] . Interestingly, we also show Prussian Blue co-staining with F480 positive cells, suggestive of iron nanoparticle signal uptake by macrophages in the joint. This likely suggests phagocytosis of apoptotic MSCs by joint macrophages. However, unlike Daldrup et al., we do not see a diminishment in repair properties due to apoptotic MSCs. In fact, the DMM mice showed the same degree of cartilage degradation with or without MSC injection, 4 weeks post-MSC injection. Recently exosomes from pluripotent stem cellderived MSCs were reported to improve cartilage degradation in a DMM model [23] .
However, the authors used repeated MSC exosome injections (every 3 days over a 4-week period) to achieve this effect. Here, we used a single MSC injection, which also decreased the amount of injury to the synovial joint upon delivery of treatment. In addition, there were xeno-and tissue-source differences: Wang et al. used human embryonic stem cellderived MSCs while we used murine femur-derived MSCs [23] .
In fact, we showed that despite the potential apoptosis of MSCs, there was an increased skewing of macrophages to more homeostatic lineages, based on expression of CD206, relative to mice receiving placebo controls. CD206 is a classical marker of more homeostatic macrophages, as a mannose receptor involved in phagocytosis ( [24] [25] [26] .
Recently it has been suggested that apoptosis of MSCs may in fact enhance their immunosuppressive properties, eliciting an IL10, IDO and TGFβ1 suppressive response similar to efferocytosis of apoptotic cell debris [27, 28] as we have observed.
Macrophages are key mediatory cells of synovial inflammation or synovitis, a hallmark characteristic of OA pathology [29] . We have recently shown that prevalence of proinflammatory monocytes/macrophages in knee OA patients inversely correlates to worsening patient-reported outcomes [14] . Others have similarly reported that prevalence of folate-receptor (i.e., activated) macrophages correlates with OA severity [30] . Proinflammatory monocytes/macrophages produce inflammatory and degradatory mediators [31] , activate T cells and the complement system [31] , and inhibit chondrogenesis in vitro [32] .
Others have also previously reported that MSC injection into DMM models does not result in improvement to cartilage scores, consistent with our results in this study, and indeed with our clinical observations in a 12 patient MSC knee OA trial (Chahal et al., in press [7] ). Schelbergen et al. have previously shown that adipose tissue-derived (AT) MSCs improved synovitis outcomes, which are pronounced in a collagenase-induced OA (CIOA) model, but not in a DMM model [33] . Unlike this study, which primarily reported AT-MSC-mediated reduced synovitis in the CIOA, we did investigate changes to inflammation even in this mild-inflammatory model, and report that bone marrow MSC treatment does rescue synovial inflammation.
There is a need to specifically track MSCs following infusion to evaluate their migration within the arthritis joint, and to quantify their accumulation and persistence at the target, and elsewhere in the body. This in turn will enable better dosing and design of Phase II clinical investigations. Our findings show feasibility of using ferumoxytol (Feraheme™) for tracking short-term persistence and biodistribution of MSCs. Ferumoxytol as an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) (DIN # 02377217). Importantly, we showed no differences in murine and human ( Fig S2) MSCs in terms of their viability, cell surface markers or tri-lineage differentiation capacity. Fe-MSCs were similar to unlabeled MSCs in terms of blood chemistry and gross histopathology of target organs (heart and spleen) (Table S2 and S3 ). This is important to note as some adverse findings have been reported with intravenous use of ferumoxytol at doses that are 600-fold higher than what we propose for ex-vivo labeling of MSCs (only 10% of MSCs will be labeled in a clinical infusion scenario). Recently, off-label use of ferumoxytol as a contrast agent (single 5 mg/kg or 4x doses) in 49 pediatric patients and 19 adults showed no serious adverse events and 4 mild, self-resolving adverse events [34] . This dose is 6.67-fold greater than the 0.75 mg dose we are proposing. Three investigation new drug applications (IND) (NCT02006108, NCT01336803 and NCT02893293) using ferumoxytol as a contrast agent were approved by the FDA; one clinical trial application (CTA, NCT02466828) using ferumoxytol as a contrast agent was approved by Health Canada. These proposed doses are 120-fold lower than the approved intra-venous dose, and about 6.67-fold higher than what we would propose to use in a clinical tracking study of MSCs. In this trial, we plan to inject up to 10% ferumoxytol-labeled MSCs of the total dose (10% labeled MSCs + 90% unlabeled MSCs) and track them at different time points by MRI imaging. Our findings lay the ground work for a clinical pharmacokinetics/pharmacodynamics study of MSCs in osteoarthritis. Our findings confirm an anti-inflammatory mechanism of action of MSCs in osteoarthritis.
Summary
We have shown that ferumoxytol-labeled murine MSCs can be tracked by MRI imaging in murine osteoarthritic joints without adverse events for up to 4 weeks. Ferumoxytol labeling of MSCs caused no alterations in viability, gene expression (except for HGF) or tri-lineage differentiation potential. Ferumoxytol-labeled MSCs persisted for a longer period of time in surgically-injured DMM mice joints than in SHAM controls. Persistence of the ferumoxytol label in MSCs was confirmed by double staining of Sca-1+ positive cells with Prussian Blue. The presence of Prussian Blue staining in neighboring macrophages argues for efferocytosis of apoptotic MSCs, which has recently been shown as a viable mechanism that enhances MSC immunomodulation. We report for the first time that DMM mice receiving MSCs had an increased proportion of homeostatic polarized macrophages in the arthritic joint than control groups, suggesting that MSCs can have anti-inflammatory effects on OA synovitis. Taken together, our imaging study provides new insights into MSC mechanism of action and lays the groundwork for clinical tracking studies using ferumoxytol-labeled MSCs.
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